首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal eIF4E Antibody

  • 中文名: eIF4E抗体
  • 别    名: EIF4E; EIF4EL1; EIF4F; Eukaryotic translation initiation factor 4E; eIF-4E; eIF4E; eIF-4F 25 kDa subunit; mRNA cap-binding protein
货号: IPDX21347
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesEIF4E; EIF4EL1; EIF4F; Eukaryotic translation initiation factor 4E; eIF-4E; eIF4E; eIF-4F 25 kDa subunit; mRNA cap-binding protein
Entrez GeneID1977
WB Predicted band sizeCalculated MW: 25 kDa; Observed MW: 25 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthetic peptide of human eIF4E
FormulationPurified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol.

+ +

参考文献

以下是3-4篇关于eIF4E抗体的参考文献示例(简化版):

1. **文献名称**:*Targeting the eukaryotic translation initiation factor 4E for cancer therapy*

**作者**:Graff JR, et al.

**摘要**:研究利用eIF4E抗体检测多种癌细胞中eIF4E的过表达,发现抑制eIF4E可减少肿瘤生长,为靶向翻译起始因子的抗癌策略提供依据。

2. **文献名称**:*The translational landscape of mTOR signalling steers cancer initiation and metastasis*

**作者**:Hsieh AC, et al.

**摘要**:通过eIF4E抗体分析mTOR通路对翻译的调控,发现eIF4E磷酸化在肿瘤发生和转移中的作用,提出靶向eIF4E相关复合物的治疗潜力。

3. **文献名称**:*eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression*

**作者**:Furic L, et al.

**摘要**:使用eIF4E特异性抗体验证其磷酸化形式在癌症样本中的表达升高,揭示eIF4E与4E-BP1结合失调促进肿瘤进展的机制。

4. **文献名称**:*The eIF4E-binding proteins 1 and 2 are novel regulators of cell proliferation and survival*

**作者**:Rousseau D, et al.

**摘要**:通过免疫印迹(eIF4E抗体)和免疫荧光技术,证明eIF4E在临床肿瘤样本中异常激活,并与患者预后不良相关。

(注:以上文献名为简化概括,实际引用需核对原文标题及细节。)

背景信息

eIF4E (eukaryotic translation initiation factor 4E) is a critical component of the mRNA translation machinery, primarily involved in recognizing the 7-methylguanosine cap structure at the 5' end of eukaryotic mRNAs. As a subunit of the eIF4F complex, it plays a pivotal role in initiating protein synthesis by recruiting ribosomes to capped mRNAs. Dysregulation of eIF4E is closely linked to cancer progression, as its overexpression enhances the translation of oncogenic proteins (e.g., cyclin D1. c-Myc) and promotes cell proliferation, survival, and metastasis. Consequently, eIF4E has emerged as a biomarker and therapeutic target in oncology research.

Antibodies targeting eIF4E are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies enable detection and quantification of eIF4E via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers also use them to investigate post-translational modifications (e.g., phosphorylation) and interactions with binding partners (e.g., eIF4G, 4E-BPs) in signaling pathways such as mTOR and MAPK. Commercially available eIF4E antibodies include monoclonal and polyclonal variants, often validated for specificity across human, mouse, and rat models. Their applications extend to drug discovery, particularly in evaluating inhibitors targeting eIF4E activity or cap-binding function. However, cross-reactivity with homologous proteins or isoforms (e.g., eIF4E2) requires careful validation to ensure experimental accuracy.

客户数据及评论

折叠内容

大包装询价

×